Prime Medicine Advances Wilson Disease Pipeline With New Prescreening Study

Prime Medicine, Inc. (PRME) announced an update on their ongoing clinical study.

Study Overview
Prime Medicine, Inc. is running an observational prescreening study called “Prescreening Study to Identify Potential Participants for a Clinical Study in Wilson Disease (WD) Due to the ATP7B p.H1069Q or p.R778L Mutations.” The goal is to better understand how people with Wilson disease live with and manage their condition and to find those who may qualify for a future gene-editing clinical trial. This work is an early but important step toward bringing a new, potentially one-time treatment option to a rare liver disease that still has limited long-term solutions.

Intervention/Treatment
This study does not test a drug or procedure yet. Instead, it screens and surveys patients who have Wilson disease with specific ATP7B gene changes (p.H1069Q or p.R778L). The purpose is to collect background information and identify candidates for a later interventional trial that will evaluate Prime Medicine’s gene-editing approach for Wilson disease.

Study Design
The study is observational and cohort-based. All enrolled participants are followed in the same general way, and there is no random assignment to different treatments. There is no masking or placebo because no active therapy is given at this stage. The main purpose is to gather real-world data and build a pool of eligible patients for an upcoming gene-editing clinical trial.

Study Timeline
The study was first submitted on October 22, 2025, marking the formal start of regulatory and site setup work. The trial is currently listed as “recruiting,” indicating active enrollment. No primary or final completion dates are posted yet, which is typical for an early prescreening effort focused on building a future trial pipeline. The most recent update was submitted on February 2, 2026, showing that the listing and operational details are being kept current as the project progresses.

Market Implications
For investors, this update confirms Prime Medicine’s continued push to apply its gene-editing platform in Wilson disease, a niche but meaningful rare disease market. While the prescreening study itself will not generate efficacy data, it signals that a first-in-human interventional trial could follow, which is often a key catalyst for sentiment and valuation in early-stage biotech. The move also positions Prime alongside other genetic medicine players focusing on liver and metabolic diseases, including companies working with gene therapy and CRISPR-based tools. Successful recruitment and clean execution here would support confidence in Prime’s development capabilities and could improve the perceived probability of future clinical milestones. Conversely, slow enrollment or operational delays could weigh on the stock in a sector where timelines and execution are closely watched. Overall, the update reinforces a steady, long-term development story rather than a near-term revenue event.

The study remains ongoing and updated, with further details available on the ClinicalTrials portal.

To learn more about PRME’s potential, visit the Prime Medicine, Inc. drug pipeline page.